European Commission approves JV between Fresenius and Sistema

The European Commission has cleared under the EU Merger Regulation the  creation of a joint venture between Germany’s Fresenius KGaA and Sistema JSFC of the Russian Federation.

The joint venture will manufacture and distribute pharmaceutical products, in particular hepatitis B vaccines and a range of biotech medications, as well as infusion and blood substitution solutions, parenteral and enteral nutrition and generic oncological treatments in the Russian Federation and the Commonwealth of Independent States (CIS).

Fresenius is a global health care group that develops and sells medicines and technologies for infusion, transfusion and clinical nutrition, with the main focus on dialysis treatments, including hospital care and medical care of patients at home.Sistema is a publically listed investment group whose portfolio comprises stakes in predominantly Russian businesses in various sectors, including telecommunications, oil, electric power, consumer goods, high tech, and biotechnology and pharmaceuticals.